Radius Health (RDUS) Posts Wider Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Radius Health Reports First Quarter 2016 Financial and Operating Results
May 5, 2016 6:30 AM EDTRadius submitted an NDA to the US FDA for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis and reduction of fracture risk.
 An MAA for abaloparatide-SC is currently under regulatory review by the European Medicines Agency and we expect a CHMP scientific opinion in 2016.
Cash, cash equivalents and marketable securities totaled $439.8 million as of March 31, 2016.               Â
WALTHAM, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Radius or the Company) (Nasdaq: RDUS), a science-driven biopharmaceutical company that is committed to developing... More
